A 35-year-old woman with systemic lupus erythematosus (SLE) is being treated with mycophenolate mofetil (MMF). Which feature best distinguishes MMF from azathioprine (AZA) in terms of mechanism and clinical utility in autoimmune disease?

Explanation

## Distinguishing Mycophenolate Mofetil from Azathioprine ### Mycophenolate Mofetil (MMF) **Key Point:** MMF is a prodrug that is rapidly converted to mycophenolic acid (MPA), which selectively inhibits inosine monophosphate dehydrogenase (IMPDH), the rate-limiting enzyme in the de novo pathway of guanine nucleotide synthesis. Lymphocytes (especially B cells) depend heavily on this pathway and are preferentially affected. **High-Yield:** MMF has **selective lymphocyte toxicity** because T and B cells rely on IMPDH for proliferation, whereas other cell types can use salvage pathways. This selectivity translates to fewer systemic side effects. ### Azathioprine (AZA) **Key Point:** Azathioprine is a prodrug converted to 6-mercaptopurine (6-MP), which is then metabolized to active metabolites that inhibit both purine synthesis and DNA/RNA synthesis. This inhibition is **non-selective** and affects all rapidly dividing cells. ### Comparative Table | Feature | Mycophenolate Mofetil (MMF) | Azathioprine (AZA) | |---------|------------------------------|---------------------| | **Prodrug conversion** | MMF → MPA (rapid) | AZA → 6-MP → active metabolites | | **Target enzyme** | IMPDH (de novo pathway) | HGPRT, TPMT (purine metabolism) | | **Selectivity** | Lymphocyte-selective (B > T) | Non-selective (all dividing cells) | | **GI toxicity** | Diarrhea, nausea (common) | Mild | | **Bone marrow suppression** | Mild | Marked (dose-dependent) | | **Hepatotoxicity** | Rare | Moderate risk | | **TPMT testing** | Not required | Required (genetic polymorphism) | | **SLE efficacy** | Superior for lupus nephritis | Moderate | | **Cost** | Higher | Lower | **Mnemonic:** **IMPDH = Immune Preferential De novo Guanine synthesis** — MMF blocks this pathway selectively in lymphocytes. **Clinical Pearl:** In SLE nephritis, MMF is now preferred over AZA due to superior efficacy in preventing renal progression and better tolerability in long-term use. MMF achieves remission in ~40% of lupus nephritis patients versus ~25% with AZA. **Warning:** Do NOT confuse MMF with calcineurin inhibitors (option D)—MMF is an antimetabolite, not a calcineurin inhibitor. Option B describes AZA, not MMF. Option C describes the metabolism of AZA, not MMF.